Sanofi Aktie

Kaufen

Verkaufen

Sanofi Aktien-Sparplan Sanofi Aktien-Sparplan

103,42 EUR +0,60 EUR +0,58 %

12:15:05

STU

103,25 EUR +0,29 EUR +0,28 %

11:09:31

BTE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.129,61 Mrd. EUR

KGV20,81Div. Rendite4,19%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

12.09.24GlobeNewswirePress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

12.09.24EN, Sanofi-AventisPress Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

11.09.24ZacksSanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

WerbungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

11.09.24BenzingaSanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

11.09.24GlobeNewswirePress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

11.09.24EN, Sanofi-AventisPress Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

11.09.24GlobeNewswirePress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

11.09.24EN, Sanofi-AventisPress Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

10.09.24EN, Sanofi-AventisMedia Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

04.09.24MotleyFoolWhy Sanofi Stock Was Robustly Healthy Today

03.09.24BenzingaSanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials

02.09.24GlobeNewswirePress Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

02.09.24EN, Sanofi-AventisPress Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

26.08.24EN, Sanofi-AventisMedia Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.